Microsatellite-stable tumors with high tumor mutational burden in association with tumor response to immune checkpoint inhibitor therapy across solid tumors and correlation with specific oncogenic alterations

被引：0
|
作者：
Nizamuddin, Imran
Doukas, Peter
de Viveiros, Pedro Antonio Hermida
Mi, Xinlei
Katam, Neelima
Chae, Young Kwang
Behdad, Amir
Wehbe, Firas Hazem
Mahalingam, Devalingam
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[3] Northwestern Univ, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2634
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [41] Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatinbased chemotherapy and immune checkpoint blockade (ICB)
    Ree, Anne Hansen
    Bousquet, Paula A.
    Nilsen, Hilde L.
    Luders, Torben
    Wang, Shixiong
    Visnovska, Tina
    Bordin, Diana L.
    Hoye, Eirik
    Hamre, Hanne M.
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne G.
    Sorbye, Halfdan
    Flatmark, Kjersti
    Meltzer, Sebastian
    CANCER RESEARCH, 2024, 84 (06)
  • [42] Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort.
    Hainsworth, John
    Friedman, Claire F.
    Kurzrock, Razelle
    Spigel, David R.
    Burris, Howard
    Sweeney, Christopher J.
    Meric-Bernstam, Funda
    Wang, Yong
    Levy, Jonathan
    Shames, David
    Schulze, Katja
    Patel, Arisha
    Swanton, Charles
    CANCER RESEARCH, 2021, 81 (13)
  • [43] Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness
    Quintanilha, Julia C. F.
    Storandt, Michael H.
    Graf, Ryon P.
    Li, Gerald
    Keller, Rachel
    Lin, Douglas I.
    Ross, Jeffrey S.
    Huang, Richard S. P.
    Schrock, Alexa B.
    Oxnard, Geoffrey R.
    Chakrabarti, Sakti
    Mahipal, Amit
    JCO PRECISION ONCOLOGY, 2023, 7
  • [44] Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration
    Hu-Lieskovan, Siwen
    Braiteh, Fadi
    Grilley-Olson, Juneko E.
    Wang, Xiao
    Forgie, Alison
    Bonato, Vinicius
    Jacobs, Ira A.
    Chou, Jeffrey
    Johnson, Melissa L.
    TARGETED ONCOLOGY, 2021, 16 (06) : 773 - 787
  • [45] Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration
    Siwen Hu-Lieskovan
    Fadi Braiteh
    Juneko E. Grilley-Olson
    Xiao Wang
    Alison Forgie
    Vinicius Bonato
    Ira A. Jacobs
    Jeffrey Chou
    Melissa L. Johnson
    Targeted Oncology, 2021, 16 : 773 - 787
  • [46] Identification of Three Core Secretome Genes Associated with Immune Infiltration in High Tumor Mutation Burden Across 14 Major Solid Tumors
    Wu, Huan
    Wang, Hanchu
    Jiang, Zhenyou
    Chen, Yue
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 6755 - 6767
  • [47] Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer
    Vokes, Natalie I.
    Liu, David
    Ricciuti, Biagio
    Jimenez-Aguilar, Elizabeth
    Rizvi, Hira
    Dietlein, Felix
    Xiao, Meng
    Margolis, Claire A.
    Elmarakeby, Haitham A.
    Girshman, Jeffrey
    Adeni, Anika
    Sanchez-Vega, Francisco
    Schultz, Nikolaus
    Dahlberg, Suzanne
    Zehir, Ahmet
    Janne, Pasi A.
    Nishino, Mizuki
    Umeton, Renato
    Sholl, Lynette M.
    Van Allen, Eliezer M.
    Hellmann, Matthew D.
    Awad, Mark M.
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 12
  • [48] Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors
    Yoshikawa, Yuki
    Imamura, Michio
    Yamauchi, Masami
    Hayes, C. Nelson
    Aikata, Hiroshi
    Okamoto, Wataru
    Miyata, Yoshihiro
    Okada, Morihito
    Hattori, Noboru
    Sugiyama, Kazuhiko
    Yoshioka, Yukio
    Toratani, Shigeaki
    Takechi, Masaaki
    Ichinohe, Tatsuo
    Ueda, Tsutomu
    Takeno, Sachio
    Kobayashi, Tsuyoshi
    Ohdan, Hideki
    Teishima, Jun
    Hide, Michihiro
    Nagata, Yasushi
    Kudo, Yoshiki
    Iida, Koji
    Chayama, Kazuaki
    BMC CANCER, 2022, 22 (01)
  • [49] Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors
    Yuki Yoshikawa
    Michio Imamura
    Masami Yamauchi
    C. Nelson Hayes
    Hiroshi Aikata
    Wataru Okamoto
    Yoshihiro Miyata
    Morihito Okada
    Noboru Hattori
    Kazuhiko Sugiyama
    Yukio Yoshioka
    Shigeaki Toratani
    Masaaki Takechi
    Tatsuo Ichinohe
    Tsutomu Ueda
    Sachio Takeno
    Tsuyoshi Kobayashi
    Hideki Ohdan
    Jun Teishima
    Michihiro Hide
    Yasushi Nagata
    Yoshiki Kudo
    Koji Iida
    Kazuaki Chayama
    BMC Cancer, 22
  • [50] Clinical Validation of Tumor Mutational Burden (TMB) in Solid Tumors by NGS: Impact of Revised TMB-High Threshold
    Parimi , Vamsi
    Xian, Rena
    Lin, Ming-Tseh
    Eshleman, James
    Gocke, Christopher
    Pallavajjala, Aparna
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 1071 - 1072
12345